&Partners’s 10x Genomics TXG Stock Holding History

&Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$289K	Buy	13,620 +281	+2%	+$5.62K	﹤0.01%	2019
2025 Q4	$218K	Buy	+13,339	New	+$202K	﹤0.01%	2098

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

&Partners's TXG Position: Q1 2026 in Review

&Partners increased its 10x Genomics (TXG) stake by 2.1% in Q1 2026, buying an estimated $5.62K and bringing the position to 13,620 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

&Partners first reported a position in TXG in Q4 2025 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

&Partners held 13,620 shares of 10x Genomics worth $289K as of Q1 2026.
&Partners bought 281 10x Genomics shares in Q1 2026, an estimated $5.62K.
10x Genomics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2019 holding.
&Partners first reported a position in 10x Genomics in Q4 2025 and has held it in 2 quarters since.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.